Jevtana Delays Disease Progression, Prolongs Survival in Men with mCRPC, Phase 4 Trial Shows

Jevtana Delays Disease Progression, Prolongs Survival in Men with mCRPC, Phase 4 Trial Shows
The chemotherapy agent Jevtana (cabazitaxel) is better than a second course of androgen receptor inhibitors at delaying disease progression and prolonging survival among men with metastatic castration-resistant prostate cancer (mCRPC), a Phase 4 trial shows. All of the participants had seen their disease progress while previously receiving androgen receptor-targeted agent therapy and docetaxel. The trial’s findings were shared in a late-breaking presentation, titled "CARD: Randomized, open-label study of cabazitaxel (CBZ) vs abiraterone (ABI) or enzalutamide (ENZ) in metastatic castration-resistant prostate cancer (mCRPC)," at the European Society for Medical Oncology (ESMO) 2019 Congress, held Sept. 27 to Oct. 1 in Barcelona, Spain. The results also were simultaneously published in The New England Journal of Medicine. Jevtana is a chemotherapy agent marketed by Sanofi Genzyme now used to treat men with advanced forms of prostate cancer. The effects of Jevtana in combination with prednisone in delaying disease progression and prolonging the life of men with mCRPC are currently being investigated in the Sanofi-sponsored, open-label, randomized, CARD Phase 4 trial (NCT02485691). CARD has enrolled a total of 255 men with mCRPC whose disease progressed after receiving androgen receptor-targeted agent therapy — Zytiga (abiraterone) or Xtandi (enzalutamide) — and docetaxel. The trial spans 62 clinical sites spread across 13 European countries. Participants were randomly assigned to receive either Jevtana administered intravenously every three weeks or a different androgen receptor-targeted agent. Those who had previously been treated with Xtandi now received Zytiga plus prednisone, while those who had previously been treated with Zytiga were now given Xta
Subscribe or to access all post and page content.